Clinical experience of digestive medicine in patients with chronic atrophic gastritis
慢性萎缩性胃炎患者的消化内科临床治疗体会

摘要

目的 讨论慢性萎缩性胃炎患者实施消化内科治疗的临床体会。方法 实验时间跨度为期一年，于2023年10月开始，至2024年9月结束，将该该期间收治慢性萎缩性胃炎患者作为观察主体，共计人数80例，将2023年10月-2024年9月收治患者40例作为对照组（行常规治疗），将2023年10月-2024年9月收治患者40例作为观察组（开展消化内科综合治疗），统计不同治疗结果，观察对比差异表现。结果 在不同治疗影响下，两组患者获得治疗结局出现明显差异，且观察组症状积分（胃胀、腹泻、上腹剧痛、泛酸嗳气）、复发率均低于对照组，观察组临床疗效数据、幽门螺旋菌转阴率均优于对照组，P值均显示＜0.05标准，有可比性；两组患者治疗期间不良反应发生率无明显差异，P＞0.05。结论 慢性萎缩性胃炎患者开展消化内科综合治疗效果确切，能够有效舒缓患者胃胀、腹泻、上腹剧痛等症状表现，提高幽门螺旋菌转阴率，控制复发，且不良反应较少，显示良好安全性，值得采纳。

Abstract

Objective To discuss the clinical experience of implementing digestive internal medicine treatment for patients with chronic atrophic gastritis.
Methods The study spanned one year, from October 2023 to September 2024. A total of 80 patients with chronic atrophic gastritis were treated during this period. 40 patients treated in 2023.10-2024.9 as the control group (received routine treatment) and 40 patients treated in 2023.10-2024.9 as the observation group (received comprehensive digestive internal medicine treatment). The outcomes of different treatments were statistically analyzed, and the differences were observed and compared.
Results Under the influence of different treatments, there were significant differences in the treatment outcomes between the two groups. The symptom scores (gastric distension, diarrhea, severe upper abdominal pain, acid regurgitation, belching), and recurrence rates of the observation group were all lower than those of the control group. The clinical efficacy data and Helicobacter pylori negativity rate of the observation group were better than those of the control group, with P values <0.05, indicating comparability. There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period, with P>0.05.
Conclusion   Comprehensive digestive internal medicine treatment for patients with chronic atrophic gastritis is effective. It can effectively alleviate symptoms such as gastric distension, diarrhea, and severe upper abdominal pain, improve the Helicobacter pylori negativity rate, control recurrence, and has fewer adverse reactions, demonstrating good safety and is worth adopting.